Microfluidics Market Size, Share, Growth and Segmentation 2020 to 2027

The global microfluidics market is expected to reach US$ 43,398.7 million in 2027 from US$ 11,851.1 million in 2019; it is estimated to grow at a CAGR of 17.9% from 2020 to 2027. Microfluidics involves various systems that can process small quantities of fluids by using tiny channels having dimensions in micrometers. It is an emerging technology having a wide range of applications in biology, chemistry, optics, and information technology. This technology is widely used in techniques such as capillary electrophoresis, sample injection in mass spectrometry, immunoassays, flow cytometry, DNA analysis, separation and manipulation of cells, and PCR amplification. Additionally, microfluidics is also used in disease research and diagnosis. The rising demand for microfluidics technologies in point-of-care testing and innovation in microfluidics products are the major factors contributing to the growth of the global microfluidics market. However, the market growth is restrained by the lower adoption of these products in emerging economies.

Request for sample PDF copy at: https://www.theinsightpartners.com/sample/TIPHE100000953/?openpr-10144

Agilent Technologies, Inc.; BD, Bio-Rad Laboratories Inc.; Danaher; Dolomite Microfluidics (Blacktrace Holdings Ltd.); Fludigm Corporation; Illumina, Inc.; microfluidic ChipShop GmbH, Perkin Elmer, Inc., and Thermo Fisher Scientific Inc.; are among the leading companies operating in the microfluidics market.

The increasing technological advancements in diagnostic devices and the rising incidence of chronic diseases are encouraging the adoption of microfluidics in disease diagnosis. The market is witnessing the launch of numerous technologically advanced products, such as 3D lab-on-a-chip devices. These advancements are leading to the evolution of a cost-effective mass-production process of diagnostic devices in a wide range of diagnostic applications. Also, key market players have been introducing new products to strengthen their market position.

In 2019, the devices segment held the largest share of the market based on product; the segment is expected to register a significant CAGR during the forecast period. The market for this segment is likely to witness lucrative growth owing the ability of devices to synthesize nanoparticles and nanocomposites, due to the efficient heat and mass transfers and spatial limitations in microfluidic devices, convenient parameter adjustments, and in situ process monitoring in microreactors. Moreover, the microfluidic devices are used in the single-cell trapping, automated micro-robotic injection, and drug discovery and analysis, among other applications. Thus, the above-mentioned factors is likely to anticipate in the growth of devices in the market.

The global microfluidics market, based on material, is segmented into PDMS, polymers, glass, silicon, and others. The PDMS segment held the largest share of the market in 2019, and it is further anticipated to register a significant CAGR during 2020–2027.

Application-Based Insights

The global microfluidics market, based on application is segmented into in-vitro diagnostics, pharmaceutical and life science research, drug discovery, and other applications. In 2019, the In-vitro diagnostics segment accounted for the largest share of the market, and it is further expected register the highest CAGR from 2020 to 2027.

Strategic Insights

Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios, which help them meet the growing consumer demand. The microfluidics market players adopted these strategies to enlarge their respective customer bases; this also permits them maintain their brand name globally.

The Laboratory of Integrated Bio-Medical/Nanotechnology & Applications (LIBNA) designed a microfluidic point-of-care sepsis chip; this chip can quantify white blood cell counts and CD64 expression levels on neutrophils in 30 minutes. Sepsis is a life-threatening complication, and the condition is cause of the highest burden of death and medical expenses worldwide. As per the Sepsis Alliance, it affects over 30 million people and causes 8 million deaths each year worldwide. Additionally, the researchers at Columbia University School of Engineering and Applied Science has developed mChip-Ld, for the early diagnosis of Lyme disease. With cases of Lyme disease on the rise, and a lack of highly specific clinical manifestations, rapid detection of the disease is crucial. As per the Centers for Disease Control and Prevention (CDC), the US reports ~300,000 Lyme disease cases every year.

Buy Complete Report at: https://www.theinsightpartners.com/buy/TIPHE100000953/?openpr-10144

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

This release was published on openPR.